Communiqués

15/06 Kintara Therapeutics : TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers PU
19/05 Kintara Therapeutics : Corporate Presentation (HURA Investor Deck Final May 2026) PU
15/05 Kintara Therapeutics : TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update PU
06/03 Kintara Therapeutics : Corporate Presentation (HURA Corporate Deck March 2026 FINAL) PU
15/01 Kintara Therapeutics : Corporate Presentation (TuHURA Corporate Deck JPM 2026 FINAL) PU
12/12/24 Kintara Therapeutics : TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc Form 8 K PU
24/10/24 TuHURA Biosciences Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC AQ
23/10/24 TuHURA Biosciences to Present at the Virtual Investor New to the Street Event AQ
21/10/24 Kintara Therapeutics : TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics Form 8 K PU
16/10/24 Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 AQ
15/10/24 Kintara Therapeutics : Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 Form 8 K PU
15/10/24 Kintara Therapeutics : Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 Form 8 K PU
09/10/24 Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update AQ
08/10/24 Kintara Therapeutics : CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 8 K PU
08/10/24 Kintara Therapeutics : Announces Fiscal 2024 Financial Results and Provides Corporate Update Form 8 K PU
07/10/24 Kintara Therapeutics : Annual Report for Fiscal Year Ending June 30, 2024 (Form 10-K) PU
04/10/24 Kintara Therapeutics : Proxy Results Form 8 K PU
23/09/24 Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 AQ
19/09/24 Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences AQ
12/09/24 Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study AQ
20/08/24 TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer AQ
12/07/24 Kintara Therapeutics : Certificate of Incorporation/Bylaws Form 8 K PU
09/07/24 TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor AQ
02/07/24 Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline near Term Milestones AQ
10/05/24 Kintara Therapeutics : Shareholder Meeting - Form 8-K PU
Aucun résultat pour cette recherche
DERNIÈRES HEURES | -40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT